



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/726,752 | 12/02/2003 | Ian Richard Buxton | PU4727US-1 | 6812 |

23347 7590 03/09/2007

GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY, MAI B475
FIVE MOORE DR., PO BOX 13398
RESEARCH TRIANGLE PARK, NC 27709-3398

| |
|----------|
| EXAMINER |
|----------|

RAMACHANDRAN, UMAMAHESWARI

| | |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

1617

| SHORTENED STATUTORY PERIOD OF RESPONSE | MAIL DATE | DELIVERY MODE |
|--|------------|---------------|
| 31 DAYS | 03/09/2007 | PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-11, drawn to a method of treating a CNS disorder comprising administering a patient therapeutically effective amount of lamotrigine, classified in class 514, subclass 241.
- II. Claim 12, drawn to a method of reducing the incidence of at least one adverse event associated with the administration of lamotrigine, classified in class 514, subclass 241.
- III. Claims 13-33, drawn to a sustained release formulation of lamotrigine, classified in class 514, subclass 241.
- IV. Claims 13, 34-42, drawn to a sustained release formulation of lamotrigine comprising a core (lamotrigine), an outer coating covering said core, said outer coating including one or more orifices extending from the outside of the coating, classified in class 514, subclass 241.
- V. Claim 43, 44 drawn to a method of achieving a serum concentration wherein upon administration to a patient of a sustained release formulation of lamotrigine, classified in class 514, subclass 241.

The inventions of Groups I, II and V and Group III and IV are related to each other as method of use and pharmaceutical composition. The inventions are distinct if the following can be shown: (1) that the method as claimed can be carried out

Art Unit: 1617

with a different product or (2) that the product as claimed can be used for a different method. (See MPEP § 806.05(h). In the instant case the method in the claims can use norcispripide in the treatment of a CNS disorder (U.S. 5,877,188).

Inventions of Groups I, II and V are related as methods of treating a CNS disorder comprising administering a patient therapeutically effective amount of lamotrigine, method of reducing the incidence of at least one adverse event associated with the administration of lamotrigine, method of achieving a serum concentration wherein upon administration to a patient of a sustained release formulation of lamotrigine and Group III and IV drawn to a sustained release formulation of lamotrigine.

The searches of Groups I-V may be overlapping but there is no reason to believe that the searches would be co-extensive. Because these inventions are distinct for the reasons given above and the search required for Groups I, II and V is not required for Group III and IV restriction for examination purposes as indicated is proper. Also, the search required for Group III is not required for Group IV, restriction for examination purposes as indicated is proper. In searching Group I, the examiner will be focusing on the method of treating a CNS disorder whereas in searching group III examiner will be focusing on a method of reducing the incidence of at least one adverse event and in searching Group V on a method of achieving a serum concentration. The search for all inventions would place an undue burden on the Office in view of the corresponding diversity in the field of search for each.

Art Unit: 1617

The examiner has required restriction between process and product claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection is governed by 37 CFR 1.116; amendments submitted after allowance is governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between products claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product

Art Unit: 1617

claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

The application contains claims directed to patentably distinct species of the claimed invention. If Applicant elects Group I Applicant is required to elect a species of a CNS disorder. If Applicant elects Group II Applicant is required to elect a species of an adverse event.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record

Art Unit: 1617

showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C 103(a) of the other invention.

Election

A telephone call to the attorney is not required where 1) the restriction requirement is complex, 2) the application is being prosecuted pro se, or 3) the examiner knows from past experience that a telephone election will not be made (MPEP § 812.01). Therefore, since the examiner knows from past experience that written restriction is preferred, a telephone election was not made.


Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Umamaheswari Ramachandran whose telephone number is 571-272-9926. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



SREENI PALMANABHAN
SUPERVISORY PATENT EXAMINER